Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)DivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Cash from Financing Activities: 2017-2024

Historic Cash from Financing Activities for BridgeBio Pharma (BBIO) over the last 8 years, with Dec 2024 value amounting to $748.5 million.

  • BridgeBio Pharma's Cash from Financing Activities fell 226.45% to -$894,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $835.4 million, marking a year-over-year increase of 209.41%. This contributed to the annual value of $748.5 million for FY2024, which is 65.76% up from last year.
  • BridgeBio Pharma's Cash from Financing Activities amounted to $748.5 million in FY2024, which was up 65.76% from $451.5 million recorded in FY2023.
  • In the past 5 years, BridgeBio Pharma's Cash from Financing Activities registered a high of $748.5 million during FY2024, and its lowest value of -$13.1 million during FY2022.
  • In the last 3 years, BridgeBio Pharma's Cash from Financing Activities had a median value of $451.5 million in 2023 and averaged $395.6 million.
  • As far as peak fluctuations go, BridgeBio Pharma's Cash from Financing Activities plummeted by 101.78% in 2022, and later soared by 3,537.91% in 2023.
  • Yearly analysis of 5 years shows BridgeBio Pharma's Cash from Financing Activities stood at $447.2 million in 2020, then soared by 64.68% to $736.4 million in 2021, then tumbled by 101.78% to -$13.1 million in 2022, then soared by 3,537.91% to $451.5 million in 2023, then spiked by 65.76% to $748.5 million in 2024.